secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0000950170-24-059109
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel Therapeutics Q1 net loss $8.2M; highlights positive CAN-2409 pancreatic cancer survival data
--------------------------------------------------------------------------------

- Net loss $8.2M vs $8.8M YoY; R&D expenses $4.1M, G&A $3.8M.
- Cash $25.7M as of March 31, 2024; expected to fund operations into Q4 2024.
- CAN-2409 pancreas phase 2: median OS 28.8 months vs 12.5 months control; 24-month survival 71.4% vs 16.7%.
- Phase 2 CAN-2409 NSCLC topline OS data to be presented at ASCO on June 3, 2024.
- Phase 3 CAN-2409 prostate cancer disease-free survival data expected in Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000095017024059109/0000950170-24-059109-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000095017024059109/cadl-20240514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-059109

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer